NeuroScientific Biopharmaceuticals (ASX:NSB) confirmed that the clinical preparation for the first patient to receive the first of four treatments, under the special access program in fistulising Crohn's disease, began, according to a Friday ASX filing.

It said it had progressed the proposed acquisition of the StemSmart patented stem cell technology from Isopogen WA.

The treatments will begin on or around June 2, with evaluation to be conducted over eight to ten weeks. Fistulas are one of the most severe complications associated with Crohn's disease and are challenging to treat, the filing noted.

The first patient, along with another three patients, will together form the first cohort of patients tested under the program.

Early indications from a phase two trial in refractory Crohn's disease suggest that StemSmart technology is efficacious and safe, per the filing. If the program is successful, it will progress to a phase 1/2 clinical trial.